Oncopeptides is a Swedish biotech, founded in 2000 and listed on Nasdaq Stockholm (ONCO), that develops cancer drugs on two platforms: peptide-drug conjugates (PDCs) and SPiKE. Its marketed drug is Pepaxti (melflufen), a peptide-drug conjugate given with dexamethasone for multiple myeloma. Pepaxti is authorized in the European Union, the EEA, and the UK for patients who have had at least three prior lines of therapy and whose disease is triple-class refractory.
On June 12, 2026, the company said it had submitted a Type II variation to the EMA to move Pepaxti into third-line treatment. The CHMP adopted a positive opinion on September 17, 2026 for patients whose disease is refractory to lenalidomide after at least two prior lines, and a European Commission decision is expected within 30 to 60 days. The U.S. history is different: the FDA withdrew the drug's approval, under the name Pepaxto, on February 23, 2024, after the confirmatory OCEAN trial did not confirm its clinical benefit.
See #melflufen, #peptide-drug-conjugate, and #multiple-myeloma.
Oncopeptides reported on October 9, 2026 that in the open-label INSULA window-of-opportunity study at Oslo University Hospital, active drug was found in resected tumor tissue from the first three patients with recurrent glioblastoma given melflufen, its EMA-approved peptide-drug conjugate, before surgery, meeting the study's primary goal of showing the drug crosses the blood-brain barrier. The company said tumor drug levels matched what animal studies predicted but gave no numbers, and the study is not designed to show clinical benefit. It plans to enroll about 10 patients and will discuss the data in an investor webcast on October 12.
Oncopeptides announced on Thursday, September 17, 2026 that the European Medicines Agency's CHMP adopted a positive opinion to extend the indication of Pepaxti (melflufen), given with dexamethasone, to adults with multiple myeloma who have had at least two prior lines of therapy and whose disease is refractory to lenalidomide and to the last line of therapy. Pepaxti's current EU label covers fourth-line and later patients whose disease is triple-class refractory, so the change would drop that requirement; the opinion rests on the Phase 3 OCEAN trial, and the European Commission is expected to decide within 30 to 60 days. Oncopeptides CEO Sofia Heigis said the broader label 'effectively doubles' the company's addressable patient population. The FDA withdrew the U.S. approval of the same drug, sold there as Pepaxto, on February 23, 2024, after concluding that the OCEAN confirmatory trial did not confirm its clinical benefit.
Oncopeptides announced on Monday, May 11, 2026 that it intends to submit a Type II variation application to the European Medicines Agency to extend the Pepaxti (melflufen) label to third-line multiple myeloma, with first regulatory feedback expected before the end of 2026 and a European Commission decision in the first half of 2027. Pepaxti, a peptide-drug conjugate given with dexamethasone, is authorized in the EU for adults who have had at least three prior lines of therapy and whose disease is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. The company said a third-line label would double Pepaxti's addressable patient population in Europe. The drug is not available in the U.S.: the FDA withdrew its approval, under the name Pepaxto, on February 23, 2024.
Oncopeptides AB (Nasdaq Stockholm: ONCO) will present preclinical data on its SPiKE platform at AACR 2026, showing synergistic effects when combining an affibody-derived bispecific engager with expanded adaptive NK cells (ADAPT-NK) in a humanized multiple myeloma mouse model. The approach leverages peptide-scaffold targeting to direct NK-cell cytotoxicity at malignant plasma cells in difficult-to-treat cancers.